What does a British worker’s Ebola diagnosis change for a response that already crosses borders? Some context before today’s development: The Democratic Republic of the Congo declared its Bundibugyo Ebola outbreak on May 15. The response has struggled to reach everyone exposed: ECDC’s November 3 update put contact follow-up at 84 percent, below a 95 percent target. Kenya and Nigeria have also confirmed imported infections, making cross-border surveillance and cooperation central to containment. This is Ebola Watch. Where do vaccines and treatments stand for Bundibugyo—and what can Uganda’s specialists bring to Congolese teams? First, the vaccine question.
From Mariam Sunny & Jennifer Rigby at The Independent:
The healthcare worker, who has not been named, was sent to the DRC by a humanitarian organisation in a bid to support the response to the outbreak. A Foreign Office spokesperson said: “A British citizen currently in the DRC has tested positive for Ebola. The risk to the UK public from Ebola remains low.”
The Independent’s November fourth report makes that vaccine question painfully specific: Bundibugyo. If somebody hears that Ebola vaccines already exist, can they assume those shots protect a healthcare worker in this outbreak? They shouldn’t assume that. The approved vaccines and treatments described here target Zaire ebolavirus; the report says Bundibugyo has no specific approved options. Experimental candidates are being evaluated, and evidence for using existing Ebola treatments against Bundibugyo is still limited to animal studies. Animal studies—that’s a substantial distance from knowing something will help a sick person. Families hearing about an experimental option deserve that distinction before they hear the hopeful part. And the DRC outbreak we’ve been following now includes a British healthcare worker who tested positive, according to that report. Britain’s Foreign Office still assesses the risk to the UK public as low; the worker’s diagnosis alone doesn’t establish wider transmission in Britain.
This one's from SaharaWire:
A team of infectiologists from Uganda's Makerere University has visited the Ebola treatment center in Aru, Ituri province, Democratic Republic of Congo, to provide technical and logistical support in the fight against the disease. The visit was confirmed by Jacques Amanga Amaa, medical chief of the Aru health zone. The Ugandan team is part of a collaboration between the DRC and Uganda, which has deployed 14 personnel to contribute to infection control in the region.
Uganda has deployed 14 personnel to help with infection control in Congo, and Makerere University specialists have visited the treatment center in Aru. That puts actual people behind the cross-border agreement—people who can help a ward work more safely. SaharaWire's November fourth report says the visit assessed those deployed staff and identified improvements. Aru is in Ituri province, in northeastern Congo; this gives the Kinshasa–Kampala health agreement a practical role inside an Ebola treatment center. And Aru's medical chief, Jacques Amanga Amaa, says patients are arriving with advanced disease. Four deaths reported there—I'd want that staff support reaching the people helping patients get into care, too. Dr. Amanga attributes the deaths to late arrival. The report also gives a 16 percent mortality figure, but we shouldn't treat that as an individual's odds of dying, or infer a confirmed-case total from it. The concrete priority he identifies is getting patients into care earlier.
If you’re finding Ebola Watch useful, please subscribe and leave a review wherever you’re listening. Your feedback helps other people find the show, and it helps us keep bringing you clear, timely updates.
Links to every story are in the show notes, so take a look at the ones you’d like to read more closely. That’s Ebola Watch for today. We’ll be back Monday. This is a Lantern Podcast.